Basic Principles of High-Precision Weapons Use in Warfare (Land Force Artillery and Missile Troops)
In: Voennaja mysl': voenno-teoretičeskij žurnal ; organ Ministerstva Oborony Rossijskoj Federacii, Band 20, Heft 2, S. 110-117
ISSN: 0236-2058
4 Ergebnisse
Sortierung:
In: Voennaja mysl': voenno-teoretičeskij žurnal ; organ Ministerstva Oborony Rossijskoj Federacii, Band 20, Heft 2, S. 110-117
ISSN: 0236-2058
In: Revista de Investigaciones Universidad del Quindío, Band 34, Heft S2, S. 330-336
ISSN: 2500-5782
This article attempts to consider a number of controversial issues regarding the definition of the nature, essence (including the concept and signs) and the purpose of the procedural legal regime in the theory of procedural legal regulation. The procedural and legal regime, as an element of the procedural-legal form, unfortunately, has not received sufficient development in legal science; a gap, in particular, remains the issues of establishing the characteristics of the category under consideration, without which it is impossible to establish the nature, essence and purpose of the procedural and legal regime. This remark is also true in relation to the definition of the concept of a procedural and legal regime, since the approaches available in legal science, for the most part, do not reveal the features and unique legal nature of the category under study. The authors of the article, on the basis of establishing the essential features of the procedural and legal regime, proposed its authentic definition, as based on a certain combination of procedural and legal means and principles of a special procedure for procedural and legal regulation of activities of subjects and participants in the legal process, aimed at legal and reasonable consideration and resolution of legal cases.
In: Journal of the International AIDS Society, Band 17, Heft 4S3
ISSN: 1758-2652
IntroductionEuroSIDA has previously reported a poorer clinical prognosis for HIV‐positive individuals in Eastern Europe (EE) as compared with patients from other parts of Europe, not solely explained by differences in patient characteristics. We explored regional variability in self‐reported HIV management at individual EuroSIDA clinics, with a goal of identifying opportunities to reduce the apparent inequalities in health.MethodsA survey (www.chip.dk/eurosida/csurvey) on HIV management was conducted in early 2014 in all currently active EuroSIDA clinics. Responders in EE were compared with clinics in all other EuroSIDA regions combined (non‐EE). Characteristics were compared between regions using Fishers exact test.ResultsA total of 80/97 clinics responded (82.5%, 12/15 in EE, 68/82 in non‐EE). Participating clinics reported seeing a total of 133,532 patients [a median of 1300 per clinic (IQR 700–2399)]. The majority of clinics requested viral load and CD4 measurements at least every six months for patients on as well as off ART (EE 66.7%, non‐EE 75%, p=0,72). Significantly fewer EE clinics performed resistance tests before ART as well as upon treatment failure (Figure 1). Half of the EE clinics indicated following WHO guidelines (EE 50%, non‐EE 7.4%, p<0.0001), whereas most non‐EE clinics followed EACS guidelines (non‐EE 76.5%, EE 41.7%, p=0.017). The majority of EE clinics and ¼ non‐EE clinics indicated deferral of ART initiation in asymptomatic individuals until CD4 ≤350 cells/mm3 (Figure 1). There were no significant regional differences in screening haematology, liver or renal function, which the majority of clinics reported to do routinely. However, EE clinics reported screening significantly less for cardiovascular disease (CVD), and only about half screened for tobacco use, alcohol consumption and drug use (Figure 1). Screening for cervical cancer and for anorectal cancer was low in both regions (Figure 1).ConclusionsWe found significant regional variability in self‐reported HIV management across Europe, with less resistance testing, screening for CVD and substance use in EE. EE clinics indicated deferral of ART initiation for longer than non‐EE clinics. Adherence to international guidelines for cervical cancer screening was poor in both regions. Whether differences in HIV management are reflected in clinical outcomes deserves further investigation.
To access publisher's full text version of this article click on the hyperlink below ; According to guidelines all HIV-HBV-coinfected patients should receive tenofovir-based combination antiretroviral therapy (cART). We aimed to investigate uptake and outcomes of tenofovir-based cART among HIV-HBV patients in the EuroSIDA study. All hepatitis B surface antigen (HBsAg)+ patients followed up after 1 March 2002 were included. Changes in the proportion taking tenofovir-based cART over time were described. Poisson regression was used to investigate the relationship between tenofovir use and clinical events. 953 HIV-HBV patients were included. Median age was 41 years and patients were predominantly male (85%), White (82%) and ART-experienced (88%). 697 and 256 were from Western and Eastern Europe, respectively. 55 started cART during follow-up, the proportion starting with CD4 Although use of tenofovir-based cART among HIV-HBV patients has increased across Europe, a substantial proportion are still starting cART late and are receiving suboptimal HBV therapy. ; European Union's Seventh Framework Programme for research, technological development and demonstration Bristol-Myers Squibb Gilead GlaxoSmithKline LLC Janssen RD Merck and Co. Inc. Pfizer Inc. Swiss National Science Foundation Danish National Research Foundation
BASE